St. Jude
The research hospital is working to further validate and refine its approach, aiming to arm clinicians with a more comprehensive tool to personalize care.
Researchers say the rare subtype of gamma-delta T-ALL, characterized by the STAG2/LMO2 rearrangement, may be vulnerable to this class of drugs.
ASH Gene Therapy Highlights in Hemophilia, TDT: Vertex Pharmaceuticals, CSL Behring, and More
Researchers at the meeting reported on the long-term activity of multiple gene therapies, including one drug with 10 years of data.
N-Lorem, St. Jude to Develop Antisense Oligonucleotide Drugs for Rare Neurological Diseases
N-Lorem will work with St. Jude's genomic medicine program to codevelop two experimental ASO therapies.
Pharmacotyping Links Childhood Leukemia Subtypes to Treatment Response
With drug sensitivity and genomic profiles on acute lymphoblastic leukemia cells, coupled with patient data, researchers saw pharmacotypes related to treatment response and outcomes.
Jul 13, 2020